The Company has more than 45 proprietary and partnered product candidates in development
Ablynx participates and presents at IR and scientific conferences
Ablynx is listed on Euronext Brussels under the ticker symbol ABLX.
ABLYNX WILL ANNOUNCE ITS 2016 FULL YEAR RESULTS WITH WEBCAST ON 23 FEBRUARY 201716 February 2017
ABLYNX TO PRESENT ADDITIONAL DATA FOR ITS ANTI-IL-6R NANOBODY, VOBARILIZUMAB, A POTENTIAL BEST-IN-CLASS TREATMENT FOR RHEUMATOID ARTHRITIS09 February 2017
ABLYNX SUBMITS A MARKETING AUTHORISATION APPLICATION TO THE EUROPEAN MEDICINES AGENCY FOR CAPLACIZUMAB, ITS ANTI-vWF NANOBODY, FOR THE TREATMENT OF aTTP 06 February 2017
TITAN study - Caplacizumab treatment for acquired thrombotic thrombocytopenic purpura